Medscape

Join us for a 15-minute live social media event with leading experts Nick Kim, MD and Marc Humbert, MD to learn about the burden of chronic thromboembolic pulmonary hypertension (CTEPH). They will discuss the latest international CTEPH registry data and how that informs evidence-based practices and the management of these patients. - - - - - Marc Humbert, MD, PhDProfessor of Medicine Université Paris-Saclay French Pulmonary Hypertension Reference Center Le Kremlin-Bicêtre, France Nick H. Kim, MD Professor of Medicine Director, Pulmonary Vascular Medicine UC San Diego Health San Diego, California - - - - - Supported by an independent educational grant from Bayer. Click the link to view the Accreditation and Disclosure details. https://lnkd.in/efKZF6iK

Join our expert faculty to hear about newly-approved drug therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM). - - - - - Faculty: Michelle M. Kittleson, MD, PhD Faculty: Ahmad Masri, MD, MS - - - - - Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event. Click the link to view the Accreditation and Disclosure details before participating: https://lnkd.in/eEu-BTeT. Supported by an independent educational grant from BridgeBio.

Diagnosing #CDiff requires a thorough approach! HCPs should consider a patient's history, symptoms, and stool tests to differentiate colonization from active infection. In severe cases, imaging can reveal complications. Stay informed beyond C.Diff Awareness Month with our partner, the Peggy Lillis Foundation.

Comprehensive and Personalized Approach to Managing mHSPC: Fitting the Right Pieces for Each Patient

CERTIFIED EVENT: This interactive session will dive into how LAIs can significantly improve treatment adherence, provide greater stability, and enhance quality of life for individuals living with schizophrenia. The patient advocate will share firsthand experiences on overcoming challenges with daily medication and how LAIs have helped maintain a steady treatment routine. We’ll discuss the benefits of reducing the frequency of medication, increasing independence, and creating a supportive treatment environment. Attendees will gain a deeper understanding of LAIs, learn how to advocate for themselves or loved ones, and discover resources for accessing these treatment options. This event promises valuable insights on improving communication between healthcare professionals and patients to achieve clinical-shared treatment decision.! - - - - - Moderator: Christoph U. Correll, MD   Faculty: Leslie Citrome, MD, MPH Patient Advocate: Max E. Guttman, LCSW - - - - - Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event. Click the link to view the Accreditation and Disclosure details before participating: https://lnkd.in/eR9xZJwi Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

In this 15-minute live social discussion, two expert faculty will explore key challenges and strategies in managing neurofibromatosis type 1-associated plexiform neurofibromas (NF-1 PNs). Discussion will cover treatment selection and initiation, the role of MEK inhibitors, adverse event management, and effective coordination across the multidisciplinary team. Practical insights from faculty are aimed at overcoming common obstacles with the goal of improving outcomes in longer-term patient care. - - - - - Faculty: Cynthia J. Campen, MD, MScE Faculty: Matthias A. Karajannis, MD MS - - - - - Earn free 0.25 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event. Click the link to view the Accreditation and Disclosure details before participating: https://lnkd.in/eBgk6gwR Supported by an independent educational grant from Alexion Pharmaceuticals, Inc.

This 30-minute live social event features two expert faculty members leading an interactive discussion focused on the care of patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1 PNs). They will explore key clinical questions informed by both real-world evidence and clinical practice insights. Discussion topics include diagnostic challenges, treatment initiation, and the management of MEK inhibitors and surgical options. Faculty will also examine adverse event management, the role of multidisciplinary teams, and available patient support resources. - - - - - Faculty: Matthias A. Karajannis, MD MS Faculty: Cynthia J. Campen, MD, MScE - - - - - Earn free 0.50 AMA PRA Category 1 CreditT™. Access for credit will be shared at the end of this live event. Click the link to view the Accreditation and Disclosure details before participating: https://lnkd.in/eKM-8w9v. Supported by an independent educational grant from Alexion Pharmaceuticals, Inc.

𝐋𝐈𝐕𝐄 𝐓𝐎𝐃𝐀𝐘! Don't miss back-to-back discussions at 12p + 1p ET re: neurofibromatosis type 1-associated plexiform neurofibromas (NF1 PNs). 🟣 12:00p ET: Key Questions, Expert Answerss http://ms.spr.ly/6043WQKXl 🔵 1:00p ET: Improving Patient and Clinician Realities http://ms.spr.ly/6044WQKXm

Stroke prevention with anticoagulation is imperative, but bleeding risk is a common problem. Could factor XIa inhibition be the solution? Manesh Patel, MD Professor of Medicine Chief, Division of Cardiology Duke University School of Medicine Durham, North Carolina, United States Ashkan Shoamanesh, MD Associate Professor of Medicine (Neurology) McMaster University / Population Health Research Institute Hamilton, Ontario, Canada Earn free 0.25 AMA PRA Category 1 CreditTM. Access for credit will be shared at the end of this live event. Click the link to view the Accreditation and Disclosure details before participating: https://lnkd.in/ei-6KHqk Supported by an independent educational grant from Bayer.

𝐖𝐀𝐓𝐂𝐇 𝐋𝐈𝐕𝐄 𝐈𝐍 𝟏 𝐇𝐎𝐔𝐑 ➡️ http://ms.spr.ly/6044Wv8oA Don't miss this LIVE CTEPH chat! In just 15 minutes you'll learn more about the disease burden and the latest data to inform evidence-based practices and patient management.